fda approval for tirzepatide GROUNDBREAKING UPDATE! has approved TIRZEPATIDE, a pioneering obesity treatment activating GIP & GLP-1 receptors, weight loss! Previously, has been FDA approved for type 2 diabetes as Mounjaro, and although Tirzepatide is FDA-approved for weight

doi: 10.7150/ijbs.59965 11

Responder rates tell a similar story within each separate trial

One study [64] found that ACC glutamate levels were decreased in individuals who used cannabis regularly, while these results were not replicated in another study [65]

They are losing weight visibly and feeling more capable, which (per Morgan Stanleys February 2024 survey of ~300 GLP-1 users) tracks with weekly workout rates jumping from 35% to 77% after starting the drug

We can learn valuable lessons from companies like Tesla and Apple to see how they collect user data to continually improve their products for both current and new customers